What You Should Know:
- Protai, a proteomics and AI-powered drug discovery startup revolutionizing the way new drugs are discovered, today announced a $12 million extension of its seed round, bringing the total amount to $20M.
- The round includes existing investors Grove Ventures and Pitango Healthcare and was joined by Copenhagen-based Maj Invest Equity Fund. The additional funding will be used to build Protai’s oncology drug discovery pipeline, expand data
Read More
Oncology Technology Solutions, Services Impacting Patients and Providers
Drug Development: Allucent Expands Use of Medidata Clinical Cloud
What You Should Know:
- Medidata announced that Allucent, a contract research organization (CRO) bringing innovation to biopharma companies, is expanding the global use of Medidata’s Clinical Cloud to advance its end-to-end clinical trial operations offering.
- The agreement expands Allucent’s existing utilization of Medidata technologies. These include Rave EDC, eCOA, RTSM,
Read More
COTA and GTC Partner to Improve Precision Oncology
What You Should Know:
- COTA, Inc., an oncology real-world data and analytics company, today announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company.
- GTC has a very innovative approach to genetic testing, providing molecular information which is critical to determining accurate diagnoses and determining the most appropriate treatment. GTC's tissue and liquid-biopsy testing leverages DNA and RNA sequencing, which is very rare in the
Read More
Tempus, Pfizer Partner to Advance Oncology Therapeutic Development
What You Should Know:
- Today, the AI-powered genetic testing and precision medicine company Tempus announced that it has signed a significant strategic agreement with Pfizer to more precisely gather insights that will inform novel drug discovery and development in oncology.
- Through this collaboration, Pfizer has access to Tempus’ AI-enabled platform and its library of de-identified, multimodal data to uncover insights that will power therapeutic development in oncology.
-
Read More
Tempus Forms Multi-omics Collaboration With Actuate Therapeutics
What You Should Know:
- Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others are combined during analysis to improve research and enable new discoveries, including ones that would have been missed with a single method alone.
- This multi-omics approach is being used by Actuate Therapeutics in support
Read More
Addressing the Diversity Challenge in Clinical Research Through Patient Advocacy
Diversity is paramount to the success of clinical research, both ethically and scientifically. Without adequate representation of racial and ethnic minorities, investigators lack an understanding of the safety and efficacy of novel treatments within those groups. From a scientific standpoint, an incomplete dataset hinders drug delivery and the development of breakthrough therapies – but from an ethical standpoint, underrepresentation creates a barrier to treatment options for populations that
Read More
Vysioneer & Pfizer Partner on AI-Powered Oncology Clinical Trials
What You Should Know:
- Vysioneer, a provider of applied AI for Oncology, today announced a data-sharing agreement with Pfizer, a global leader in pharmaceuticals. The agreement aims to lay the foundation for the application of AI in oncology clinical trials.
As part of the agreement, Vysioneer gains access to one of Pfizer's oncology clinical trial datasets to apply Vysioneer's advanced machine-learning techniques to facilitate the drug efficacy assessment process, thereby allowing Pfizer
Read More
5 Components of a Patient-Centric eCOA Strategy for Oncology Clinical Trials
In the US alone, an estimated 1.9 million new cases of cancer were diagnosed in 2022, positioning oncology as a key subject of clinical research. Throughout oncology trial development, it is important that stakeholders acknowledge that only patients can fully understand the impact of treatment on their lives. Regulators are now looking beyond clinical indications such as tumor size and delayed disease progression. When evaluating the risks and benefits of treatment, they want to know whether the
Read More
RTLS Can Enhance the Patient Experience, Staff Safety, and Workflow Operations in 2023
Although the healthcare industry has shown significant resilience, the byproduct of the pandemic has amplified staff stressors across all operational and clinical roles. In a study conducted in 2022, more than one-third (34%) of the participating registered nurses (RN) stated that it was likely they would leave bedside nursing by the end of the year. Almost half (44%) cited both burnout and high-stress environments as their main reasons to retire or pursue other careers.
As staff
Read More
Epic, Impact Advisors, Nordic, Chartis Named 2023 Overall Best in KLAS® Awards
What You Should Know:
Epic, Nordic, Impact Advisors and The Chartis Group won the 2023 Overall Best in KLAS® awards. Epic was named the top Overall Software Suite for the thirteenth straight year in 2023 Best in KLAS – Software & Services report, released, which reports on the top vendors for 2022. Epic was also named the top Overall Physician Practice Vendor. Epic won thirteen other Best in KLAS awards in various market segments.
- Impact Advisors tied with Nordic to be a
Read More
